Glioma

REVIEW
Year
: 2022  |  Volume : 5  |  Issue : 2  |  Page : 56--61

Overcoming T-cell exhaustion in glioblastoma: A narrative review


Xuya Wang1, Xisen Wang1, Jiabo Li2 
1 Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China
2 Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China; Department of Pathology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Il, USA

Correspondence Address:
Mr. Xisen Wang
Department of Neurosurgery, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin 300052
China

Immunotherapy is typically ineffective against glioblastoma (GBM) due to inherent and adaptive resistance. Initial immunotherapy results for GBM have been disappointing. In this regard, T-cell exhaustion is a major barrier to successful treatment. The recognition of exhausted CD8+ T cell (Tex) pedigree is currently undergoing a paradigm shift. This review introduces major findings in this field to provide an up-to-date perspective on epigenetic, transcriptional, metabolic, and spatial heterogeneity, as well as interactions with tumor microenvironment cells of anti-tumoral CD8+ Tex from the following aspects: (i) Epigenetic and transcriptional mechanisms underlying T-cell exhaustion, (ii) Metabolic factors underpinning T-cell exhaustion, (iii) Contribution of multiple cell types to T-cell exhaustion, (iv) Occurrence of T-cell exhaustion at multiple locations, and (v) T-cell exhaustion may not always be terminal. These novel insights afford a wide range of new therapeutic approaches to overcome T-cell exhaustion in GBM.


How to cite this article:
Wang X, Wang X, Li J. Overcoming T-cell exhaustion in glioblastoma: A narrative review.Glioma 2022;5:56-61


How to cite this URL:
Wang X, Wang X, Li J. Overcoming T-cell exhaustion in glioblastoma: A narrative review. Glioma [serial online] 2022 [cited 2022 Oct 2 ];5:56-61
Available from: http://www.jglioma.com/article.asp?issn=2589-6113;year=2022;volume=5;issue=2;spage=56;epage=61;aulast=Wang;type=0